Precision BioSciences Inc (FRA:PBS0)
€ 9.85 -0.25 (-2.48%) Market Cap: 65.13 Mil Enterprise Value: -34.23 Mil PE Ratio: 0 PB Ratio: 2.02 GF Score: 54/100

Precision BioSciences Inc at H.C. Wainwright & Co LLC 4th Annual Hepatitis B Virus (HBV) Conference (Virtual) Transcript

Oct 25, 2023 / 01:30PM GMT
Release Date Price: €6.72 (-5.88%)
Patrick Trucchio
H.C. Wainwright & Co., LLC - Analyst

Welcome back, everyone, to the 4th Annual H.C. Wainwright HBV Conference. My name is Patrick Trucchio. I'm a senior healthcare analyst at H.C. Wainwright. It's my pleasure to introduce our next speaker, Cassie Gorsuch, VP of Gene Therapy at Precision BioSciences, an advanced gene editing company dedicated to improving life with the novel ARCUS genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure.

So with that, let's start with some background on the ARCUS platform, history of its development, and data that's been generated to date that underpins the in vivo gene editing pipeline.

Cassie Gorsuch
Precision BioSciences, Inc. - VP, Gene Therapy

Yeah. Thanks, Patrick. Thanks for having me here today.

So as you mentioned, Precision is a gene editing company. So we are developing proprietary gene editors that we call ARCUS nucleases. And so these nucleases are really differentiated from a lot of the other nucleases in

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot